Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824448 | 0.92 | ALOX12 (0.55) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL3824195 | 0.89 | ALOX12 (0.62) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL3827572 | 0.86 | ALOX12 (0.58) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL3825546 | 0.84 | ALOX12 (0.70) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL3824454 | 0.83 | ALOX12 (0.54) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL27796557 | 0.82 | ADRA2A (0.44) | ALOX12SMN1; SMN2PLK4CHEK1AURKA | |
| SCHEMBL3824001 | 0.81 | ALOX12 (0.62) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL14159725 | 0.80 | ALOX12 (0.65) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL3820585 | 0.79 | ALOX12 (0.63) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 | |
| SCHEMBL3822096 | 0.79 | ALOX12 (0.63) | ALOX12SMN1; SMN2CHRM1PLK4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040036-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | LIU JIN-JUN | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | CDK2, CDK1, CDK7 | ALOX12 4573/4885SMN1; SMN2 4537/4885CHRM1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.